Rigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M
Source: SeekingAlpha
2025-11-04 16:24:30 ET
More on Rigel Pharmaceuticals
- Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
- Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
- Seeking Alpha’s Quant Rating on Rigel Pharmaceuticals
- Historical earnings data for Rigel Pharmaceuticals
- Financial information for Rigel Pharmaceuticals
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals GAAP EPS of $1.46 beats by $0.56, revenue of $69.46M beats by $7.58M
Rigel Pharmaceuticals Inc.
NASDAQ: RIGL
RIGL Trading
2.96% G/L:
$26.10 Last:
91,444 Volume:
$26.02 Open:
RIGL Latest News
March 16, 2026 06:56:37 pm
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
March 03, 2026 04:01:00 pm
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RIGL Stock Data
$625,132,287
16,430,597
0.07%
54
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
